Controversies in Alzheimer's disease drug development

ISSN： 1369-1627

Source： International Review of Psychiatry, Vol.20, Iss.4, 2008-08, pp. : 389-395

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biomarkers to advance drug development for Alzheimer’s disease

By Schulman Howard

Future Neurology, Vol. 1, Iss. 4, 2006-07 ,pp. : 409-415

Future Medicine

Access to resources Recommend Favorite

Novel approaches to models of Alzheimer’s disease pathology for drug screening and development

By Shaughnessy Laura Chamblin Beth McMahon Lori Nair Ayyappan Thomas Mary Wakefield John Koentgen Frank Ramabhadran Ram

Journal of Molecular Neuroscience, Vol. 24, Iss. 1, 2004-02 ,pp. : 23-32

Humana Press, Inc

Access to resources Recommend Favorite

A New Regulatory Road-Map for Alzheimer’s Disease Drug Development

Current Alzheimer Research, Vol. 11, Iss. 3, 2014-03 ,pp. : 215-220

Bentham Science Publishers

Access to resources Recommend Favorite

Resurrecting Clinical Pharmacology As a Context for Alzheimer Disease Drug Development

Current Alzheimer Research, Vol. 6, Iss. 1, 2009-02 ,pp. : 79-81

Bentham Science Publishers

Access to resources Recommend Favorite

Drug discovery for Alzheimer’s disease: The end of the beginning

By Refolo Lorenzo Fillit Howard

Journal of Molecular Neuroscience, Vol. 24, Iss. 1, 2004-02 ,pp. : 1-8

Humana Press, Inc

Access to resources Recommend Favorite